“Black Box” Gives Black Eye To Prospects For COX-2 Ads Returning
This article was originally published in The Tan Sheet
Executive Summary
While an FDA advisory committee voted strongly in favor of allowing continued marketing of Celebrex (celecoxib), the panel's recommendations for warnings diminish the prospects of renewed DTC marketing
You may also be interested in...
PPI Marketers Target Patients Leaving COX-2s For NSAIDs
Proton pump inhibitor marketers are poised to benefit from potential cardiovascular risk warnings for COX-2 inhibitors that could increase the migration of arthritis patients to traditional NSAIDs
PPI Marketers Target Patients Leaving COX-2s For NSAIDs
Proton pump inhibitor marketers are poised to benefit from potential cardiovascular risk warnings for COX-2 inhibitors that could increase the migration of arthritis patients to traditional NSAIDs
PPI Marketers Target Patients Leaving COX-2s For NSAIDs
Proton pump inhibitor marketers are poised to benefit from potential cardiovascular risk warnings for COX-2 inhibitors that could increase the migration of arthritis patients to traditional NSAIDs